Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | IDO1 | P14902 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MLKL | Q8NB16 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406845 | 1.00 | ALDH1A1 (1.00) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL9675207 | 0.84 | POLB (0.72) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL31210108 | 0.81 | ALDH1A1 (0.68) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL3483731 | 0.81 | ALDH1A1 (0.68) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL9214713 | 0.81 | ALDH1A1 (0.68) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL10636343 | 0.80 | ALDH1A1 (0.66) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL85832 | 0.79 | ALDH1A1 (0.66) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL4921708 | 0.79 | IDO1 (1.00) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL2147079 | 0.79 | ALDH1A1 (0.66) | ALDH1A1POLBIDO1NPSR1KDM4E | |
| SCHEMBL7533794 | 0.79 | ALDH1A1 (0.66) | ALDH1A1POLBIDO1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113745539-B | Fluorine-containing non-noble metal oxygen reduction electrocatalyst and preparation method and application thereof | 大连理工大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114656405-A | Preparation method of difluoromethylbenzimidazole | 广州和为医药科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-113745539-A | Fluorine-containing non-noble metal oxygen reduction electrocatalyst and preparation method and application thereof | 大连理工大学 | 2021-12-03 | — | — | CN | claimed |
| EP-2817294-B1 | PROCESS FOR PRODUCTION OF DFMB DERIVATIVES | RHODIA OPERATIONS (FR) | 2017-12-27 | — | — | EP | claimed |
| US-9458119-B2 | Process for production of DFMB derivatives | RHODIA OPERATIONS (FR) | 2016-10-04 | — | — | US | claimed |
| US-20150005505-A1 | Process for production of DFMB derivatives | RHODIA OPERATIONS (FR) | 2015-01-01 | — | — | US | claimed |
| EP-2817294-A1 | PROCESS FOR PRODUCTION OF DFMB DERIVATIVES | Rhodia Operations (FR) | 2014-12-31 | — | — | EP | claimed |
| WO-2013123634-A1 | PROCESS FOR PRODUCTION OF DFMB DERIVATIVES | RHODIA OPERATIONS (FR) | 2013-08-29 | — | — | WO | claimed |
| CN-118812553-A | Fluorine-containing functionalized macrocyclic supermolecule main body molecular cup and preparation method and application thereof | 上海大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812553-A | Fluorine-containing functionalized macrocyclic supermolecule main body molecular cup and preparation method and application thereof | 上海大学 | 2024-10-22 | — | — | CN | disclosed |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118063453-A | Benzimidazole derivative, preparation method and application thereof, and agricultural bactericide | 南京吉星生物技术开发有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114149418-B | High morpholine compound, preparation method, pharmaceutical composition and application | 天津医科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-11774853-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-03 | — | — | US | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003024899-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-0669927-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5405938-A | Hydrogen bonding an N-heterocyclic-substituted ribose-based polymer to a double-stranded DNA to block genetic activity, to diagnose for pathogens and to aid in genetic engineering | ANTI-GENE DEVELOPMENT GROUP (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994012517-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | ALDH1A1 208/4885POLB 144/4885IDO1 1496/4885 |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | ALDH1A1 750/4885POLB 1005/4885IDO1 1349/4885 |
| US-20150005505-A1 | Process for production of DFMB derivatives | DAO, FGB, FOSB | ALDH1A1 1453/4885POLB 431/4885IDO1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.